Jing Huang, Ph.D. co-founded Westlake Pharmaceuticals in 2020 and serves as its Director.

Dr. Huang is a principal investigator in the School of Life Sciences at Westlake University and the Director of AI Therapeutics Lab at Westlake Laboratory of Life Sciences and Biomedicine (WLLSB).

He is a leading figure in both Computer-Aided Drug Design(CADD) and Artificial Intelligence-Driven Drug Design (AIDD) in China, providing scientific consulting services to AI-driven pharmaceutical companies such as XtalPi and DP Technology, as well as top Internet companies such as ByteDance, Baidu (BioMarker Technologies), and Tencent, and conducting related research in collaboration with these companies.

He received his bachelor’s degree and master’s degree in physics at Tsinghua University, and his Ph.D. in chemistry at University of Basel in Switzerland.  He did his postdoctoral training from 2012 to 2017 in the Computer-Aided Drug Design Center in University of Maryland School of Pharmacy. In 2015 he was  awarded a research contract from National Institute of Health (NIH), and thus held a joint appointment in the Laboratory of Computational Biology at the National Heart, Lung, and Blood Institute, NIH.